MTOR and cardiac hypertrophy: Notably, this hypertrophic response was prevented by rapamycin, an mTOR inhibitor, suggesting that the Akt/mTOR pathway, rather than glycogen accumulation, plays a dominant role in mediating cardiac hypertrophy associated with the N488I PRKAG2 mutation (131).